# Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)

> **NCT01045161** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 544 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Aclidinium bromide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01045161
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 544 (ACTUAL)
- **Last updated:** 2017-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01045161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01045161, "Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01045161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*